Means and methods for treating hsv

By developing a polycomplex vaccine containing HSV polypeptide, the problem of poor development of existing HSV vaccines and the inability of drugs to avoid virus reactivate is solved, and a strong immune response and potential preventive effects have been achieved.

CN118949021APending Publication Date: 2024-11-15REDBIOTEC AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410868546.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-03-14
Filing Date
2017-03-14
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing HSV vaccine development attempts focus on a limited number of antigens, which perform poorly, and existing drugs such as acyclovir cannot avoid the periodic reactivate of the virus, and effective HSV vaccines are urgently needed.

Method used

Polycomplexes containing HSV polypeptides UL11, UL16, UL21, UL48, UL49 and gE were developed as vaccine compositions to form stable polypeptide complexes through stringent protein purification methods to induce a strong immune response.

Benefits of technology

The vaccine composition is able to form a stable polypeptide complex in host cells, triggering a stronger immune response, potentially preventing or treating initial infection and periodic reactivated of HSV, beyond the limitations of existing drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004920952720000011
    Figure HDA0004920952720000011
  • Figure HDA0004920952720000021
    Figure HDA0004920952720000021
  • Figure HDA0004920952720000031
    Figure HDA0004920952720000031
Patent Text Reader

Abstract

The present invention relates to a vaccine composition comprising a multicomplex of a herpes simplex virus (HSV) polypeptide for use in the treatment of HSV or vaccination against HSV. The invention also relates to a vector comprising a polynucleotide encoding an HSV polypeptide and a host cell comprising the vector. The invention further comprises a method for producing the vaccine composition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a vaccine composition comprising a multimeric complex of herpes simplex virus (HSV) polypeptides for use in treating HSV or for vaccination against HSV. The present invention also relates to a vector comprising a polynucleotide encoding an HSV polypeptide and a host cell comprising the vector. The present invention further comprises a method for producing the vaccine composition. Background Art

[0002] Herpes simplex virus is a genus of viruses in the family of viruses called herpesviruses. The species that infect humans are commonly referred to as herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2), with their official names human herpesvirus 1 (HHV-1) and human herpesvirus 2 (HHV-2), respectively. Initial infection with HSV-1 usually occurs in childhood or adolescence and persists throughout life. The infection rate of HSV-1 is 40% to 80% worldwide and is higher in people of lower socioeconomic status. In many cases, people exposed to HSV-1 show asymptomatic seroconversion. However, the initial infection can also be severe, causing widespread 1 to 2 mm blisters, accompanied by severe discomfort that interferes with eating and drinking until dehydration, which occurs 1 to 26 days after inoculation and lasts 10 to 14 days. Recurrent cold sores affect approximately one-third of the U.S. population, and these patients typically experience 1 to 6 episodes per year. Papules on an erythematous base become vesicles within a few hours and then undergo ulceration, crusting and healing stages within 72 to 96 hours (Cernik et al., 2008, Arch Intern Med., vol. 168, pp. 1137-1144). According to global estimates in 2003, it is assumed that 16.2% of people are infected with HSV-2, which is the main cause of genital herpes. The ability of the virus to successfully evade clearance by the immune system by entering a non-replicating state called latency leads to lifelong infection. Periodic reactivation of latency is possible and causes the virus to fall off from the site of initial infection. Genital damage caused by herpes is usually very painful and can cause substantial psychological illness. Such viruses can also be transmitted from mother to child at birth. If not treated, 80% of infants with disseminated disease will die, and those who survive often suffer from brain damage. In addition, genital herpes increases the risk of HIV infection by 2 to 3 times, increases the risk of HIV transmission per sexual act by 5 times, and can account for 40% to 60% of new HIV infections in populations with high HSV-2 incidence (Looker et al., 2008, Bulletin of the World Health Organization, vol. 86, pp. 805-812).

[0003] At present, the synthetic acyclic purine-nucleoside analog acyclovir (acyclovir) is the standard therapy for HSV infection, and greatly helps to control symptoms. Prodrugs, valacyclovir (valacyclovir) (converted into acyclovir) and famciclovir (famciclovir) (converted into penciclovir (penciclovir)) have been licensed, and have better oral bioavailability than acyclovir and penciclovir respectively. Because existing drugs are only converted into active drugs by viral thymidine kinase in virally infected cells, therefore, they have excellent safety. However, by producing thymidine kinase defective mutants or by selecting mutants with thymidine kinase that can not phosphorylate acyclovir, HSV can produce resistance to acyclovir by mutations in the viral gene encoding thymidine kinase. Although the DNA polymerase of change has been detected in some, most of the clinical HSV isolates to acyclovir resistance lack thymidine kinase. Because HSV can remain latent in neurons for months or years before becoming activated, such therapies can be used to treat symptoms caused by HSV but cannot prevent periodic reactivation of the virus.

[0004] Therefore, the most effective and economical way to fight HSV is a vaccine that prevents initial infection and / or periodic reactivation of the virus. Over the past few decades, much effort has been put into developing such vaccines. However, attempts to develop an effective HSV vaccine have focused on a limited number of antigens that have performed poorly in clinical trials. Therefore, there is an urgent need for a vaccine against HSV. Summary of the invention

[0005] Vaccine composition

[0006] The present invention meets this need and provides new vaccine compositions comprising a multimeric complex of herpes simplex virus (HSV) polypeptides UL11, UL16 and UL21, a multimeric complex of herpes simplex virus (HSV) polypeptides UL48, UL49 and gE, or a multimeric complex of herpes simplex virus (HSV) polypeptides UL31 and UL34.

[0007] The terms "multiplex" or "complex" are used interchangeably herein and refer to a stable polypeptide complex composed of at least two polypeptide subunits and any covalently linked molecules (such as lipid anchors or oligosaccharides) or non-protein prosthetic groups (such as nucleotides or metal ions). In this context, a prosthetic group refers to a tightly bound auxiliary factor. Thus, a multiplex may contain two polypeptides (i.e., dimers), three polypeptides (i.e., trimers), or four polypeptides (i.e., tetramers). The multiplexes of the present invention involve a set of interacting proteins that have been shown to exist as functional units in vivo, and the polypeptides of the multiplexes of the present invention can be co-purified using stringent protein purification methods. Such stringent protein purification methods use buffers and solutions that do not force non-specific and / or artificial protein interactions, and therefore can only purify complexes that remain intact when subjected to stringent washing conditions (i.e., the polypeptides of the complex are not released). Therefore, methods that only show polypeptide interactions, such as immunoprecipitation or pull-down experiments from cell extracts, are not considered suitable methods for purifying the complexes of the present invention. Likewise, methods that only show polypeptide colocalization or polypeptide interaction do not indicate a complex of the present invention, particularly if such methods employ artificially modified polypeptides, such as the yeast two-hybrid system. Thus, after purification, the complex of the present invention can be detected using a suitable method (e.g., size exclusion chromatography). Thus, the mere presence of two or more polypeptides in a composition (which may have been shown to exist as a complex in vivo) is not considered to be a complex of the present invention, since such a complex can be formed using only specific purification methods and conditions, and is only stable under specific storage conditions after purification. Thus, even if certain polypeptides have been shown to form complexes in vivo, the polypeptides may also exist in solution as monomers. In one embodiment, the multimeric complex is a dimer comprising HSV polypeptides UL11 and UL16. In a further embodiment, the complex is a dimer comprising HSV polypeptides UL16 and UL21. In a preferred embodiment, the complex is a trimer comprising HSV polypeptides UL11, UL16, and UL21. In a further preferred embodiment, the multimeric complex is a trimer and comprises or consists of the HSV polypeptides UL11, UL16 and UL21. In one embodiment, the multimeric complex is a dimer comprising the HSV polypeptides UL48 and UL49. In a further embodiment, the complex is a dimer comprising the HSV polypeptides UL49 and gE. In a preferred embodiment, the complex is a trimer comprising the HSV polypeptides UL48, UL49 and gE. In a further preferred embodiment, the multimeric complex is a trimer and comprises or consists of the HSV polypeptides UL48, UL49 and gE.In a further preferred embodiment, the complex is a dimer comprising or consisting of HSV polypeptides UL31 and UL34. In the multimeric complex of the present invention, one or more of the proteins may contain additional B and / or T cell epitopes. The T cell epitope may be a CD4 T cell epitope or a CD8 T cell epitope. Preferably, the complex of the present invention provides a synergistic effect. Therefore, compared to a single protein, the complex of the present invention is preferably capable of eliciting a stronger immune response in an ELISPOT assay of patient PBMCs.

[0008] The complex of the present invention can be produced using suitable means and methods known in the art. The complex of the present invention can be produced by co-expressing the individual polypeptides of the complex in a host cell so that the complex is formed in the host cell. The complex of the present invention can also be produced by expressing the individual polypeptides of the complex in separate host cells, purifying the individual polypeptides from the host cells, and mixing the individual polypeptides in vitro under conditions that allow the formation of the complex. However, the complex of the present invention can also be produced by expressing the individual polypeptides of the complex in separate host cells, purifying the individual polypeptides from the host cells, and administering the individual polypeptides to a subject so that the complex is formed in vivo. Whether the complex is formed in vivo after administering the individual polypeptides of the complex to a subject can be determined in a model system that simulates in vivo conditions (i.e., 37° C., blood, serum, and physiological salt concentration).

[0009] The polypeptide of the vaccine composition may include a tag. As used herein, a polypeptide tag is an amino acid sequence fused to a recombinant polypeptide gene that enables the polypeptide to be purified and / or detected. The polypeptide of the vaccine composition may be fused to an HA-tag, a Flag-tag, a Myc-tag, a V5-tag, a Strep-tag, a StrepII-tag, a Sof-tag, a His-Strep-tag, an Avi-tag, a Calmodulin-tag, an E-tag, an S-tag, an SBP-tag, a TC-tag, a VSV-tag, an Xpress-tag, a Ty-tag, a Halo-tag, a Nus-tag, a Thioredoxin-tag, an Fc-tag, a Chitin Binding Protein (CBP), a Maltose Binding Protein (MBP), a Glutathione-S-transferase (GST), or a Green Fluorescent Protein (GFP). In a preferred embodiment, the polypeptide of the vaccine composition is fused to a polyhistidine-tag, which may consist of 6 or 12 His-residues, preferably 8 His-residues. Preferably, the polypeptide tag is fused to the polypeptide of the vaccine composition via a polypeptide linker. A preferred combination of a polypeptide linker and an 8His-tag is shown in SEQ ID NO:10.

[0010] "Polypeptide" refers to a molecule comprising a polymer of amino acids linked together by peptide bonds. The term does not refer to a specific length of the molecule herein and is therefore used interchangeably with the term "protein" herein. When used herein, the term "polypeptide" or "protein" also includes a "polypeptide of interest" or "protein of interest" that is expressed by an expression cassette or vector or that can be isolated from a host cell of the present invention. A polypeptide comprises an amino acid sequence, and therefore, a polypeptide comprising an amino acid sequence is sometimes referred to herein as a "polypeptide comprising a polypeptide sequence". Therefore, the term "polypeptide sequence" is used interchangeably with the term "amino acid sequence" herein.

[0011] The term "amino acid" or "aa" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are subsequently modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., carbon is linked to hydrogen, carboxyl, amino, and R groups, such as homoserine, norleucine, methionine sulfoxide, methyl sulfonium of methionine. These analogs have modified R groups (such as norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.

[0012] "Epitope" refers to a part of an antigen that is recognized by the immune system (e.g., a B cell or a T cell). The term encompasses conformational and linear (or continuous) epitopes. A conformational epitope comprises a discontinuous portion of the amino acid sequence of an antigen, while a linear epitope consists of a continuous portion of the amino acid sequence of an antigen. A conformational epitope may also comprise portions of the amino acid sequence of two or more antigens. The term further includes cryptotopes and neotopes. A "cryptotope" is an epitope that is hidden in a naturally occurring antigen (e.g., a virus) but becomes accessible when the antigen is not present in its native conformation. A "neotope" is an epitope that is only found in the quaternary structure of a protein but not in a protein monomer.

[0013] B cell epitopes are regions of antigens (e.g., natural proteins) that are recognized by specific membrane-bound B-cell receptors (BCRs) or antibodies. Many methods are readily available to identify or select B-cell epitopes, including x-ray crystallography, array-based oligopeptide scanning, site-directed mutagenesis, mutagenesis mapping, and phage display, as well as computational methods such as those reviewed by Sun et al., Comput Math Methods Med. 2013; 2013: 943636. For example, suitable methods include structure-based prediction models that rely on the 3D structure of the antigen and the propensity scale associated with the epitope, including geometric properties and specific physicochemical properties. Structure-based algorithms and web servers (programs) include, for example, EPSVR & EPMeta (http: / / sysbio.unl.edu / services / ), EPCES (http: / / sysbio.unl.edu / services / EPCES / ), and Epitopia (http: / / epitopia.tau.ac.il / ). The prediction method based on mimetic epitopes is a combination method that requires peptides selected by antibody affinity and the 3D structure of the antigen as input. Exemplary algorithms and programs based on the prediction model of mimetic epitopes include such as MimoPro (http: / / informatics.nenu.edu.cn / MimoPro), PepSurf (http: / / pepitope.tau.ac.il) and EpiSearch (http: / / curie.utmb.edu / episearch.html). In addition, sequence-based prediction models are available, which only rely on the primary sequence of the antigen, for example, such as the BEST and Zhang methods reviewed in Sun et al. Comput Math Methods Med.2013; 2013:943636. In addition, a binding site prediction model can be used, which infers a method for predicting the binding site of the interaction focusing on protein-protein interaction, antigen and antibody, such as ProMate, ConSurf, PINUP and PIER.

[0014] T cell epitopes are usually derived from processed protein antigens. T cell epitopes can be CD4-T cell epitopes or CD8T- cell epitopes. Although cytotoxic (CD8) T cells recognize intracellular peptides (CD8T- cell epitopes) displayed by MHC class I molecules, T helper cells recognize peptides (CD4T- cell epitopes) obtained from the extracellular space and displayed by MHC class II molecules. Peptide: MHC complex (pMHC) interacts with T- cell receptors, thereby causing the activation of the complex and subsequently inducing cellular immune responses. Many T cell epitope predictions and / or selected computer simulations (in silico) methods are available. For CD8+ T cell epitope prediction, NetCTL-1.2 (http: / / www.cbs.dtu.dk / services / NetCTL / ), EpiJen (http: / / www.ddg-pharmfac.net / epijen / EpiJen / EpiJen.htm) or MAPPP (http: / / www.mpiib-berlin.mpg.de / MAPPP / ) as reviewed in Larsen et al. BMC Bioinformatics 2007, 8:424 can be used. For CD4+ T cells, computational models for epitope prediction have been reviewed by Oyarzún P et al. BMC Bioinformatics 2013, 14:52 and include data-driven methods that rely on peptide sequence comparison to identify binding motifs, such as Rankpep (http: / / imed.med.ucm.es / Tools / rankpep.html), TEPITOPE and NN-align (http: / / www.cbs.dtu.dk / services / NNAlign / ), as well as structure-based methods that implement molecular modeling calculations to estimate binding energies, thereby making them independent of experimental binding data, such as NetMHCIIPan-2.0 (http: / / www.cbs.dtu.dk / services / NetMHCIIpan-2.0 / ), TEPITOPEpan (http: / / www.biokdd.fudan.edu.cn / Service / TEPITOPEpan / ) and Predivac (http: / / predivac.biosci.uq.edu.au / ).

[0015] The terms "herpes simplex virus" and "HSV" are used interchangeably herein and generally refer to viruses of the genus Herpes simplex virus, i.e., Ateline herpesvirus 1, Bovine herpesvirus 2, Cercopithecine herpesvirus 1, Cercopithecine herpesvirus 2, Cercopithecine herpesvirus 16, Human herpesvirus 1, Human herpesvirus 2, Macropodid herpesvirus 1, Macropodid herpesvirus 2, Saimiriine herpesvirus 1. Preferred species of the genus Herpes simplex virus are those that infect humans. Even more preferred species are Herpes simplex virus 1 (HSV-1) and Herpes simplex virus 2 (HSV-2), which are referred to as Human herpesvirus 1 and 2 (HHV-1 and HHV-2), respectively.

[0016] The term "vaccine composition" as used herein relates to a composition comprising a multimeric complex of the present invention, which can be used to prevent or treat a pathological state associated with HSV in a subject. A "vaccine composition" may or may not contain one or more other components that enhance the immunological activity of the active component, such as a buffer, a reducing agent, a stabilizer, a chelating agent, a bulking agent, an osmotic balancer (tonicity agent); a surfactant, a polyol, an antioxidant; a lyoprotectant; a defoaming agent; a preservative; and a colorant, a detergent, a sodium salt and / or an antibacterial agent, etc. The vaccine composition may additionally contain other components commonly used in pharmaceutical compositions. The vaccine of the present invention is preferably used for human and / or veterinary use. The vaccine composition may be sterile and / or pyrogen-free. The vaccine composition may be isotonic to humans.

[0017] Preferably, the vaccine composition comprises a therapeutically effective amount of the multimeric complex of the present invention or obtainable by the method of the present invention.

[0018] Preferably, the HSV polypeptide UL11 of the vaccine composition of the present invention comprises an amino acid sequence having 75% or higher identity with the amino acid sequence of SEQ ID NO: 1, wherein the HSV polypeptide UL11 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0019] When used herein, the term "UL11" relates to the envelope protein of HSV. SEQ ID NO: 1 exemplarily depicts the amino acid sequence of HSV-2 UL11, which is also deposited in NCBI GenBank under accession number AHG54674.1. However, the term "UL11" also encompasses UL11 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO: 1, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO: 1 as described herein. Thus, the term "UL11" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 74%, 73%, 72%, 71%, 70% or preferably 75% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO: 1, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 74%, 73%, 72%, 71%, 70% or preferably 75% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO: 1. Compared with the amino acid sequence of NO:1, there are up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29 or preferably 24 amino acid substitutions, insertions and / or deletions. The preferred UL11 protein can form a complex with UL16, UL21 and / or the cytoplasmic tail of gE or gE. Therefore, the preferred UL11 protein can form a dimer with the cytoplasmic tail of UL16 or gE or gE, a trimer with UL16 and UL21 or with the cytoplasmic tail of UL16 and gE or gE and / or a tetramer with the cytoplasmic tail of UL16, UL21 and gE or gE.

[0020] "Sequence identity" or "% identity" refers to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. In order to optimize the alignment between two sequences, such an algorithm can insert gaps in the compared sequences in a standardized and reproducible manner, thereby achieving a more meaningful comparison of the two sequences. For the purposes of the present invention, the NCBI BLAST program version 2.3.0 (January 13, 2016) (Altschul et al., Nucleic Acids Res. (1997) 25: 3389-3402) is used to determine the sequence identity between two amino acid sequences. The sequence identity of two amino acid sequences can be determined using blastp with the following parameters set: matrix: BLOSUM62, word length: 3; expectation: 10; gap penalty: presence = 11, extension = 1; compositional adjustment: conditional combination score matrix adjustment.

[0021] The term "immune response" refers to the ability to induce a humoral and / or cell-mediated immune response (preferably but not limited to in vivo). Humoral immune responses include B cell-mediated antibody responses. Cell-mediated immunity includes T cell-mediated immune responses, including but not limited to CD4+T cells and CD8+T cells. The ability of an antigen to elicit an immune response is called immunogenicity, which can be a humoral and / or cell-mediated immune response. Preferably, the immune response of the present invention is an immune response to HSV, and even more preferably an immune response to HSV infection in a subject.

[0022] The ability to induce humoral and / or cell-mediated immune responses in vivo can be determined using a guinea pig model of genital HSV-2 infection, which accurately reflects the disease in humans and represents a system for testing pathogenesis and the therapeutic efficacy of candidate antiviral compounds and vaccines. This model can also serve as an ideal system to address the nature of genital-resident and neural tissue-resident immune memory. Genital infection in guinea pigs leads to self-limited vulvovaginitis, and its neurological manifestations reflect those found in human disease. Primary disease in female guinea pigs involves viral replication in genital epithelial cells, which is usually limited to 8 days. During this period, the virus reaches the sensory nerve endings and transports the virus to the cell bodies in the sensory ganglia and autonomic neurons in the spinal cord by retrograde transport. After a brief acute replication at this site, the immune system usually resolves acute viral replication on the 15th day after inoculation and maintains the virus as a lifelong latent infection of sensory neurons. After recovery from primary HSV-2 genital infection, guinea pigs experience sporadic, spontaneous, recurrent infections and diseases. HSV-2 recurrence can manifest as clinically apparent disease with erythematous and / or vesicular lesions of the perineum or as asymptomatic recurrence characterized by viral shedding from the genital tract. For example, the guinea pig genital infection model can be used to assess vaccine efficacy. 1 PFU, 5×10 2 PFU, 5×10 3 PFU, 5×10 4 PFU, 5×10 6 PFU, 5×10 7 PFU, 5×10 8 PFU or 5 × 10 9 PFU and preferably 5 × 10 5PFU of HSV-2 (such as strain MS) is intravaginally infected with animals. The animals are immunized once, twice, three times, four times, five times or more before or after infection. Preferably, the animals are immunized twice at an interval of 15 days on the 15th day after infection. Generally, any suitable route of administration can be used for immunization. However, preferably, the animals are immunized intramuscularly. A control group that simulates possible immunity is used with adjuvant only (such as CpG 100μg / Alum 150μg) or PBS (both groups are negative controls), or with HSV-2d15-29 mutant virus strain (positive control). In each round of immunization, the group immunized with the vaccine candidate in combination with the adjuvant may receive a dose of 0.1 μg, 0.5 μg, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 10 μg, 15 μg, 25 μg, 30 μg, 35 μg, 40 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 150 μg, 200 μg and preferably 20 μg of the corresponding antigen. As a readout, vaginal swabs can be collected, for example, from day 0 to day 200 post infection, day 1 to day 180 post infection, day 3 to day 160 post infection, day 5 to day 140 post infection, day 7 to day 120 post infection, day 10 to day 100 post infection, day 12 to day 90 post infection to assess the frequency and extent of recurrent viral shedding. Vaginal swabs can be collected every 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days. Preferably, vaginal swabs are collected every day from the 15th day to the 85th day after infection. In the same time interval, the severity (score 0 to 4) and the duration of recurrent genital herpes lesions are scored every day. Preferably, at the end of the study, antibody responses and CD4+ and CD8+ T cell responses are measured.

[0023] The vaccine composition of the present invention can be administered by a variety of routes, including but not limited to oral, topical, transdermal, subcutaneous, intravenous, intraperitoneal, intramuscular or intraocular. However, if desired, those skilled in the art can easily select any other route.

[0024] The exact dosage of the vaccine composition of the present invention administered to a subject may depend on the purpose of treatment (e.g., acute disease treatment versus preventive vaccination), route of administration, age, body weight, general health, sex, diet, time of administration, drug interactions, and severity of the condition, and may be determined by a person skilled in the art through routine experiments. Preferably, the administered dosage is an effective dosage, i.e., a dosage that effectively induces an immune response.

[0025] The vaccine composition of the invention can be administered to a subject once or more times, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times.

[0026] As used herein, "subject" refers to an animal, preferably a mammal, which may be, for example, a mouse, rat, guinea pig, hamster, rabbit, dog, cat or primate. Preferably, the subject is a human. However, the term "subject" also includes cells, preferably mammalian cells, even more preferably human cells. Such cells may be immune cells, preferably lymphocytes.

[0027] Preferably, the HSV polypeptide UL16 of the vaccine composition of the present invention comprises an amino acid sequence having 75% or higher identity with the amino acid sequence of SEQ ID NO:2, wherein the HSV polypeptide UL16 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0028] When used herein, the term "UL16" relates to the envelope protein of HSV. SEQ ID NO: 2 exemplarily depicts the amino acid sequence of HSV-2 UL16, which is also deposited in NCBI GenBank under accession number AHG54679.1. However, the term "UL16" also encompasses UL16 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO: 2, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO: 2 as described herein. Thus, the term "UL16" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 71%, 70%, 69%, 68%, 67% or preferably 72% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:2, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 71%, 70%, 69%, 68%, 67% or preferably 72% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:2. Compared with the amino acid sequence of NO:2, it has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 17, 18, 19, 20, 21, 22, 23 or preferably 24 amino acid substitutions, insertions and / or deletions. The preferred UL16 protein can form a complex with UL11, UL21 and / or gE or the cytoplasmic tail of gE. Thus, the preferred UL16 protein can form a dimer with UL21 or UL11, can form a trimer with UL11 and UL21 and / or can form a tetramer with UL11, UL21 and gE or the cytoplasmic tail of gE.

[0029] Preferably, the HSV polypeptide UL21 of the vaccine composition of the present invention comprises an amino acid sequence having 80% or higher identity with the amino acid sequence of SEQ ID NO: 3, wherein the HSV polypeptide UL21 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0030] When used herein, the term "UL21" relates to the envelope protein of HSV. SEQ ID NO:3 exemplarily depicts the amino acid sequence of HSV-2 UL21, which is also deposited in NCBI GenBank under accession number AHG54684.1. However, the term "UL21" also encompasses UL21 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO:3, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO:3 as described herein. Thus, the term "UL21" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 79%, 78%, 77%, 76%, 75% or preferably 80% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:3, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 79%, 78%, 77%, 76%, 75% or preferably 80% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:3. Compared with the amino acid sequence of NO:3, it has as high as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 7, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97 ,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,1 35, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 or preferably 134 amino acid substitutions, insertions and / or deletions. Preferred UL21 proteins can form a complex with UL11, UL16 and / or gE or the cytoplasmic tail of gE.Thus, the preferred UL21 protein can form a dimer with UL16, can form a trimer with UL11 and UL16 and / or can form a tetramer with UL11, UL16 and gE or the cytoplasmic tail of gE.

[0031] As described herein, the multimeric complex contained in the vaccine composition of the present invention can also be a polypeptide complex containing four polypeptides (i.e., a tetramer). Therefore, the multimeric complex of the present invention containing the HSV polypeptides UL11, UL16, and UL21 can further contain the HSV polypeptide gE. In this case, the multimeric complex of the present invention contains the HSV polypeptides UL11, UL16, UL21, and gE.

[0032] Preferably, the HSV polypeptide gE of the vaccine composition of the present invention comprises an amino acid sequence having 70% or higher identity with the amino acid sequence of SEQ ID NO:4, wherein the HSV polypeptide gE is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0033] When used herein, the term "gE" may sometimes be referred to as "glycoprotein E". SEQ ID NO: 4 exemplarily depicts the amino acid sequence of HSV-2 gE, which is also deposited in NCBI GenBank under accession number AHG54732.1. However, the term "gE" also encompasses gE polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO: 4, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO: 4 described herein.Thus, the term "gE" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 69%, 68%, 67%, 66%, 65% or preferably 70% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:4, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 69%, 68%, 67%, 66%, 65% or preferably 70% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:4. 45,46,47,48,49,50,51,52,53,54,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105 , 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154 4, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180 or preferably 165 amino acid substitutions, insertions and / or deletions. Preferred gE proteins can form complexes with UL11, UL16 and UL21. Therefore, preferred gE proteins can form dimers with UL11, trimers with UL11 and UL16, and tetramers with UL11, UL16 and UL21.

[0034] In a further preferred embodiment of the present invention, the multimeric complex comprising the HSV polypeptides UL11, UL16, UL21 contained in the vaccine composition of the present invention may also be a tetramer comprising the cytoplasmic domain of the HSV polypeptide gE. In this case, the multimeric complex of the present invention comprises the cytoplasmic domain of the HSV polypeptides UL11, UL16, UL21 and gE.

[0035] Preferably, the cytoplasmic domain of gE of the vaccine composition of the present invention comprises the amino acid sequence shown in SEQ ID NO:5. However, it is also contemplated herein that the cytoplasmic domain of gE comprises an amino acid sequence having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 79%, 78%, 77%, 76%, 75% or preferably 80% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:5, or encompasses polypeptides having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27 or preferably 23 amino acid substitutions, insertions and / or deletions compared to the amino acid sequence of SEQ ID NO:5. The preferred cytoplasmic domain of gE can form a complex with UL11, UL16 and UL21. Thus, the preferred cytoplasmic domain of gE can form a dimer with UL11, a trimer with UL11 and UL16 and a tetramer with UL11, UL16 and UL21.

[0036] Preferably, the HSV polypeptide UL48 of the vaccine composition of the present invention comprises an amino acid sequence having 80% or higher identity with the amino acid sequence of SEQ ID NO:6, wherein the HSV polypeptide UL48 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0037] When used herein, the term "UL48" relates to the envelope protein VP16 of HSV. SEQ ID NO:6 exemplarily depicts the amino acid sequence of HSV-2 UL48, which is also deposited in NCBI GenBank under accession number AHG54712.1. However, the term "UL48" also encompasses UL48 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO:6, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO:6 as described herein. Thus, the term "UL48" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 79%, 78%, 77%, 76%, 75% or preferably 80% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:6, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 79%, 78%, 77%, 76%, 75% or preferably 80% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:6. Compared with the amino acid sequence of NO:6, it has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 17, 18, 19, 20, 21, 22, 23 or 24 amino acid substitutions, insertions and / or deletions. The preferred UL48 protein can form a dimer with UL49, or can form a trimer with UL49 and gE or the cytoplasmic tail of gE.

[0038] Preferably, the HSV polypeptide UL49 of the vaccine composition of the present invention comprises an amino acid sequence having 62% or higher identity with the amino acid sequence of SEQ ID NO:7, wherein the HSV polypeptide UL49 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0039] When used herein, the term "UL49" relates to the envelope protein VP22 of HSV. SEQ ID NO: 7 exemplarily depicts the amino acid sequence of HSV-2 UL49, which is also deposited in NCBI GenBank under accession number AKC42813.1. However, the term "UL49" also encompasses UL49 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO: 7, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO: 7 as described herein. Thus, the term "UL49" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 74%, 73%, 72%, 71%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 61%, 60%, 59%, 58%, 57% or preferably 62% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:2, or encompasses polypeptides having 59%, 58%, 57% or preferably 62% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:2. 53,54,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130 or preferably 115 amino acid substitutions, insertions and / or deletions. The preferred UL49 protein can form a complex with UL48 and / or gE or the cytoplasmic tail of gE. Thus, the preferred UL49 protein can form a dimer with UL48 or gE or the cytoplasmic tail of gE, or can form a trimer with UL48 and gE or the cytoplasmic tail of gE.

[0040] In a further preferred embodiment of the present invention, the multimeric complex comprising HSV polypeptides UL48 and UL49 contained in the vaccine composition of the present invention can also be a trimer comprising the cytoplasmic domain of the HSV polypeptide gE. In this case, the multimeric complex of the present invention comprises the cytoplasmic domain of the HSV polypeptides UL48, UL49 and gE.

[0041] Preferably, the HSV polypeptide UL31 of the vaccine composition of the present invention comprises an amino acid sequence having 85% or higher identity with the amino acid sequence of SEQ ID NO:8, wherein the HSV polypeptide UL31 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0042] When used in this article, the term "UL31" relates to the virion egress protein of HSV. SEQ ID NO:8 exemplarily depicts the amino acid sequence of HSV-2 UL31, which is also deposited in NCBI GenBank under accession number AHG54695.1. However, the term "UL31" also encompasses UL31 polypeptides having an amino acid sequence that has a certain degree of identity with the amino acid sequence shown in SEQ ID NO:8, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO:8 described herein. Therefore, the term "UL31" encompasses polypeptides that have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 84%, 83%, 82%, 81%, 80% or preferably 85% or higher amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:1, or encompasses polypeptides that have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 84%, 83%, 82%, 81%, 80% or preferably 85% or higher amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:1. 54,56,57,58,59,60,61 or preferably 46 amino acid substitutions, insertions and / or deletions compared to the amino acid sequence of NO:8. The preferred UL31 protein can form a dimer with UL34.

[0043] Preferably, the HSV polypeptide UL34 of the vaccine composition of the present invention comprises an amino acid sequence having 70% or higher identity with the amino acid sequence of SEQ ID NO:9, wherein the HSV polypeptide UL34 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

[0044] As used herein, the term "UL34" relates to the virion export protein of HSV. SEQ ID NO:9 exemplarily depicts the amino acid sequence of HSV-2 UL34, which is also deposited in NCBI GenBank under accession number AHG54698.1. However, the term "UL34" also encompasses UL34 polypeptides having an amino acid sequence that has a certain degree of identity to the amino acid sequence shown in SEQ ID NO:9, and also encompasses polypeptides having mutations relative to the reference sequence shown in SEQ ID NO:9 as described herein. Thus, the term "UL34" encompasses polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 69%, 68%, 67%, 66%, 65% or preferably 70% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:9, or polypeptides having 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 69%, 68%, 67%, 66%, 65% or preferably 70% or more amino acid sequence identity compared to the amino acid sequence of SEQ ID NO:9 Compared with the amino acid sequence of IDNO:9, it has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 , 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88 or preferably 75 amino acid substitutions, insertions and / or deletions. The preferred UL34 protein can form a dimer with UL31.

[0045] As described above, each protein of the present invention may contain mutations (such as insertions, deletions and substitutions) relative to the reference sequences shown in SEQ ID NO: 1 (UL11), SEQ ID NO: 2 (UL16), SEQ ID NO: 3 (UL21), SEQ ID NO: 4 (gE), SEQ ID NO: 5 (cytoplasmic domain of gE), SEQ ID NO: 6 (UL48), SEQ ID NO: 7 (UL49), SEQ ID NO: 8 (UL31) and SEQ ID NO: 9 (UL34), as long as these mutations do not impair the use of the protein as an antigen in the vaccine composition of the present invention. In addition, such mutations should not limit the ability of the protein to form a multimeric complex of the present invention. The formation of the multimeric complex of the present invention can be tested by performing protein purification and analyzing the protein by, for example, non-reducing PAGE, Western blotting and / or size exclusion chromatography. In particular, each protein may include a tag, which may, for example, facilitate detection, purification and / or enhance solubility.

[0046] In a further preferred embodiment of the present invention, the polypeptide of the multimeric complex of the vaccine composition of the present invention is an HSV-1 polypeptide.

[0047] In a further preferred embodiment of the present invention, the polypeptide of the multimeric complex of the vaccine composition of the present invention is an HSV-2 polypeptide.

[0048] The vaccine composition of the present invention may further comprise a pharmaceutically acceptable carrier or adjuvant.

[0049] The terms "carrier" and "excipient" are used interchangeably herein. Pharmaceutically acceptable carriers include, but are not limited to, diluents (fillers, extenders, such as lactose, microcrystalline cellulose), disintegrants (such as sodium starch glycolate, cross-linked sodium carboxymethyl cellulose), binders (such as PVP, HPMC), lubricants (such as magnesium stearate), glidants (such as colloidal SiO2), solvents / co-solvents (such as aqueous carriers, propylene glycol, glycerol), buffers (such as citrate, gluconate, lactate), preservatives (such as sodium benzoate, parabens (Me, Pr and Bu), BKC), antioxidants (such as BHT, BHA, ascorbic acid), wetting agents (such as polysorbates, sorbitan esters), defoaming agents (such as dimethicone), thickeners (such as methylcellulose or hydroxyethylcellulose), sweeteners (such as sorbitol, saccharin, aspartame, acesulfame potassium), flavorings (such as mint, lemon oil, creamer, etc.), humectants (such as propylene, ethylene glycol, glycerol, sorbitol). Other pharmaceutically acceptable carriers are (biodegradable) liposomes; microspheres made of the biodegradable polymer poly (D, L) -lactic-co-glycolic acid (PLGA), albumin microspheres; synthetic polymers (soluble); nanofibers, protein-DNA complexes; protein conjugates; red blood cells or virus particles. Various carrier-based dosage forms include solid lipid nanoparticles (SLN), polymer nanoparticles, ceramic nanoparticles, hydrogel nanoparticles, copolypeptide nanoparticles, nanocrystals and nanosuspensions, nanocrystals, nanotubes and nanowires, functionalized nanocarriers, nanospheres, nanocapsules, liposomes, fat emulsions, lipid microtubules / microcylinders, lipid microbubbles, lipid spheres, lipid complexes (lipopolyplex), inverse lipid micelles (inverse lipid micelle), dendrimers (dendrimer), ethosomes, multicomposite (multicomposite) ultrathin capsules, aquasomes (aquasomes), pharmacosomes (pharmacosomes), colloidosomes (colloidosomes), vesicles (niosomes), discoid bodies (discome), proniosomes (proniosomes), microspheres, microemulsions and polymer micelles.Other suitable pharmaceutically acceptable excipients are described in particular in Remington's Pharmaceutical Sciences, 15th Ed., Mack Publishing Co., New Jersey (1991) and Bauer et al., Pharmazeutische Technologie, 5th Ed., Govi-Verlag Frankfurt (1997). Depending on the formulation and administration route of the pharmaceutical composition, a person skilled in the art will be able to easily select a suitable pharmaceutically acceptable carrier.

[0050] The term "adjuvant" as used herein refers to a substance that enhances, increases or strengthens the host's (antibody and / or cell-mediated) immune response to an antigen or fragment thereof. Exemplary adjuvants for use according to the present invention include inorganic compounds (such as alum, aluminum hydroxide, aluminum phosphate, basic calcium phosphate), TLR9 agonist CpG oligodeoxynucleotides, TLR4 agonist monophosphoryl lipids (MPL), TLR4 agonist pyranose lipids (GLA), oil-in-water emulsions Montanide ISA 51 and 720, mineral oils (such as paraffin oil), virus particles, bacterial products (such as killed bacteria Bordetella pertussis, Mycobacterium bovis), toxoids, non-bacterial organic matter (such as squalene, thimerosal), detergents (Quil A), cytokines (such as IL-1, IL-2, IL-10 and IL-12) and complex compositions (such as Freund's complete adjuvant and Freund's incomplete adjuvant). In general, the adjuvant used according to the present invention preferably enhances the immune response to the multimeric complex of the present invention and / or adjusts it toward a desired immune response.

[0051] The term "pharmaceutically acceptable" refers to non-toxic materials that do not interfere with the effectiveness of the biological activity of the multimeric complex according to the present invention.

[0052] purification

[0053] "Purification" in all its grammatical forms means the removal of undesirable compounds, such as cells, cell debris, culture medium, baculovirus, complete or incomplete baculovirus, etc. Suitable purification methods are readily available in the prior art, depending on the expression system, yield, etc. For example, purification may include ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, affinity chromatography and / or mixed mode chromatography, all of which have been extensively described previously. As described, the purification step particularly includes the removal of baculovirus. The baculovirus may be contained in the culture medium and / or supernatant that can be obtained from host cells infected with a baculovirus vector or a BacMam vector. It is preferred to remove such baculovirus when purifying the multimeric complex of the present invention.

[0054] Purification as used herein also includes the removal of host cells co-expressing HSV proteins from the culture medium. Preferably, the culture medium contains the multimeric complex of the present invention, because the host cells can secrete the multimeric complex. Removal of host cells from the culture medium can be carried out via mechanical force (such as via centrifugation or filtration). Preferably, filtration is carried out by using a filter medium (such as a microfiltration filter or a depth filter). The microfiltration filter can be composed of polyethersulfone or regenerated cellulose. The depth filter can be composed of polypropylene or glass fiber.

[0055] However, it is also contemplated that the host cell does not necessarily secrete the multimeric complex. If so, the host cell can be harvested. After harvesting, the host cell can be disrupted, for example, enzymatically or mechanically, to release the multimeric complex, which can then be purified as described herein.

[0056] After purification, it is envisaged that a chelating agent is added to the polyplex.

[0057] store

[0058] "Storage" in all its grammatical forms means storage (for future use) preferably under conditions that maintain the multimeric complex of the invention in its intact or functional form (i.e., the multimeric complex preferably resembles its naturally occurring form). It is therefore envisaged that storage conditions do not promote (or even prevent) the disintegration of the multimeric complex of the invention. The term "disintegration" is understood herein in its broadest sense and may mean "disassembly" and / or "denaturation". It is envisaged that the storage of the multimeric complex of the invention is in a buffer solution comprising a chelating agent and / or a stabilizer.

[0059] Generally speaking, any chelating agent and / or stabilizing agent is suitable as long as it is able to store the multimeric complex of the invention and does not promote its disintegration.

[0060] The buffer solution according to the present invention may include Tris buffer, NaCl, KCl, PBS, HEPES buffer.

[0061] Use of the vaccine composition

[0062] The present invention also relates to the use of the vaccine composition in a method for inducing an immune response against HSV in a subject.

[0063] In a preferred embodiment of the present invention, the vaccine composition is used to treat, prevent or ameliorate HSV infection or prevent HSV reactivation.

[0064] Thus, the vaccine composition can be used to combat diseases caused by HSV and / or related symptoms. It is also envisioned that the vaccine composition of the present invention can be used to clear the virus in a subject, i.e., after treatment, HSV cannot be detected in a suitable sample obtained from the subject using a suitable method known to those of ordinary skill in the art (e.g., PCR, ELISA, etc.). Thus, the vaccine composition of the present invention can be used to block primary infection, prevent primary disease, block viral reactivation and reinfection, and block latency.

[0065] To reduce the chance of genital herpes, a preventive vaccine is needed to prevent the mother's first HSV infection, while an effective therapy is needed in the event that the mother is diagnosed with an active HSV infection. The multimeric complexes of the present invention can be used, for example, as a preventive vaccine for pregnant women or children, or as a therapeutic vaccine in seropositive women to prevent subclinical reactivation during delivery.

[0066] In a further preferred embodiment of the present invention, the vaccine composition is used in a method for inducing an immune response against HSV-1 or HSV-2 in a subject.

[0067] Carrier

[0068] The present invention further relates to a vector comprising a polynucleotide encoding UL11, UL16 and UL21 and optionally a cytoplasmic domain of gE or gE. In a further embodiment of the present invention, the vector may also include a polynucleotide encoding UL11 and UL16. In a further embodiment of the present invention, the vector may also include a polynucleotide encoding UL16 and UL21. The present invention further relates to a vector comprising a polynucleotide encoding UL48, UL49 and a cytoplasmic domain of gE or gE. In a further embodiment of the present invention, the vector also includes a polynucleotide encoding UL48 and UL49. In a further embodiment of the present invention, the vector may also include a polynucleotide encoding UL49 and a cytoplasmic domain of gE or gE. The present invention further relates to a vector comprising a polynucleotide encoding UL31 and UL34. Typically, the genes encoding the HSV proteins of the complex of the present invention may also be present on more than one vector, for example, on two vectors. Therefore, one, two or three of the genes are on a first vector, and the remaining genes are on a second vector. However, each of the genes may also be on a separate vector. However, preferably, the genes are present on a single vector. The gene may also exist in polygenic form (EP1945773).

[0069] As used herein, the term "vector" refers to a nucleic acid sequence into which an expression cassette containing a gene encoding a protein of interest can be inserted or cloned. In addition, the vector may encode a gene that confers selective antibiotic resistance to the host cell. Preferably, the vector is an expression vector.

[0070] The vector may comprise elements for propagation in bacteria (e.g., E. coli), yeast (e.g., S. cerevisiae), insect cells, and / or mammalian cells. Preferably, the vector is a baculovirus vector or a baculovirus BacMam vector. The vector may have a linear, circular, or supercoiled structure and may be complexed with other vectors or other materials for certain purposes. The vector may also be integrated into the host cell genome.

[0071] In the BacMam system, baculovirus vectors are used to deliver genes into mammalian cells. The BacMam system can be used to deliver genes to a wide range of cell lines and primary cells as host cells, and its exemplary list is included elsewhere herein. Unmodified baculovirus can enter mammalian cells, but unless a promoter recognizable by mammals is introduced upstream of the target gene, its gene is not expressed. Therefore, it is envisioned that the BacMam vector of the present invention comprises a mammalian promoter upstream of the gene encoding the protein of the multi-complex of the present invention. The vector may comprise other elements described elsewhere herein, such as antibiotic resistance genes, elements for breeding in Escherichia coli, Saccharomyces cerevisiae, etc.

[0072] The vector may contain one or more other elements, including, for example, an origin of replication, a promoter, a cloning site, a genetic marker, an antibiotic resistance gene, an epitope, a reporter gene, a targeting sequence and / or a protein purification tag. Those skilled in the art will readily know which elements are suitable for use in a particular expression system.

[0073] In particular, the vector according to the present invention may further comprise elements for propagation in bacteria (E. coli), yeast (S. cerevisiae), insect cells and / or mammalian cells, such as an origin of replication, a selectable marker and the like.

[0074] It is envisioned that the vector comprises a promoter for gene expression. Each of the genes encoding the proteins of the present invention described herein is driven by a promoter. Preferably, the promoter is selected from the group consisting of: polh, p10 and p XIV Very late baculovirus promoter, vp39 baculovirus late promoter, vp39polh baculovirus late / very late hybrid promoter, pca / polh, pcna, etl, p35, egt, da26 baculovirus early promoter; CMV-IE1, UBc, EF-1, RSVLTR, MT, simian virus 40 promoter, CAG promoter (β-actin promoter with CMV-IE1 enhancer), hepatitis B virus promoter / enhancer, human ubiquitin C promoter, hybrid neuronal promoter, p DS47 , Ac5 and P GAL and P ADH Each of the genes is followed by a terminator sequence, such as the HSVtk terminator, the SV40 terminator or the bovine growth hormone (BGH) terminator.

[0075] The terms "polynucleotide", "nucleotide sequence" or "nucleic acid molecule" are used interchangeably herein and refer to nucleotides in a polymeric form, usually connected by one deoxyribose or ribose to another deoxyribose or ribose. Preferably, the term "polynucleotide" includes DNA or RNA in single-stranded and double-stranded forms. The nucleic acid molecules of the present invention may include RNA (containing ribonucleotides), cDNA, the sense strand and antisense strand of genomic DNA, as well as synthetic forms and mixed polymers thereof. As readily accepted by those skilled in the art, nucleic acid molecules may be chemically or biochemically modified, or may contain non-natural or derived nucleotide bases. These modifications include, for example, labeling, methylation, replacement of one or more of the naturally occurring nucleotides with analogs, internucleotide modifications such as neutral linkages (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), pendant moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylating agents, and modified bonds (e.g., α-anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic the ability of polynucleotides to bind to a specified sequence through hydrogen bonds and other chemical interactions. These molecules are known in the art and include, for example, molecules in which peptide bonds replace phosphate bonds in the molecular backbone.

[0076] Therefore, the nucleic acid as an expression product is preferably RNA, and the nucleic acid to be introduced into the cell is preferably DNA or RNA, such as synthetic DNA, genomic DNA or cDNA.

[0077] A vaccine composition is also envisioned, comprising a nucleic acid or vector encoding a polyplex disclosed herein. Such nucleic acids or vectors may be based on DNA or RNA. Suitable vectors for use according to the vaccine composition include DNA-based vectors, such as baculovirus vectors, BacMam vectors, adenovirus vectors, lentivirus vectors, AAV vectors, herpesvirus vectors, poxvirus vectors, and Eppstein-Barr virus (EBV) vectors. It is also envisioned to use naked DNA; such as in plasmid form and optionally, in a complex and / or stabilized form (such as a lipoplexe, a synthetic polymer (polyplexe), a dendrimer, a virus particle, and a complex with an inorganic nanoparticle). Suitable RNA-based vectors include reverse transcription vectors, Semliki forest virus (SFV), Sindbis virus (SIN), and Venezuelan equine encephalitis virus (VEE) vectors.

[0078] The vaccine composition comprising the polycomplex and the vaccine composition comprising the nucleic acid or vector encoding the polycomplex can be used in a prime boost regimen. In the prime boost regimen, a prime / boost vaccine consisting of two or more types of vaccines is used, and the two or more types of vaccines include vaccines used in primary immunization (prime or priming) and vaccines used in booster immunization (boost or boosting). The vaccine used in the primary immunization and the vaccine used in the booster immunization may be different from each other. The primary immunization and booster immunization can be implemented in sequence, however, this is not mandatory. The prime / boost regimen includes, but is not limited to, DNA prime / protein boost. However, the booster composition can also be used as a prime immunization composition and the prime immunization composition can be used as a booster composition.

[0079] Host cells

[0080] The present invention further relates to a host cell comprising a vector containing polynucleotides encoding UL11, UL16 and UL21 and optionally gE or the cytoplasmic domain of gE. In a further embodiment of the present invention, the host cell may also comprise a vector containing polynucleotides encoding UL11 and UL16. In a further embodiment of the present invention, the host may also comprise a vector containing polynucleotides encoding UL16 and UL21.

[0081] The present invention further relates to a host cell comprising a vector containing a polynucleotide encoding UL48, UL49 and gE or a cytoplasmic domain of gE. In a further embodiment of the present invention, the host cell may also comprise a vector containing a polynucleotide encoding UL48 and UL49. In a further embodiment of the present invention, the host may also comprise a vector containing a polynucleotide encoding UL49 and gE or a cytoplasmic domain of gE.

[0082] The present invention further relates to a host cell comprising a vector comprising a polynucleotide encoding UL31 and UL34.

[0083] The host cell may be an insect cell or a mammalian cell. The host cell may also be a bacterium (such as Escherichia coli) or a yeast (such as Saccharomyces cerevisiae). In general, any host cell suitable for expressing nucleic acid molecules to produce the multimeric complex of the present invention may be used. However, insect and mammalian host cells are preferred. Even more preferred are insect host cells. The host cells used according to the present invention may be insect cells, such as Sf9, Sf21, Super Sf9-1 (VE-1), SuperSf9-2 (VE-2), Super Sf9-3 (VE-3), Hi-5, Express Sf+ and S2 Schneider cells, of which Hi-5 is preferred [Oxford Expression Technologies, Cat. No. 600103, Oxford, UK; Fath-Goodin et al. (2006), Adv. Virus Res. 68, 75-90; Kroemer et al. (2006), J. Virol. 80 (24), 12291-12228 and US20060134743.]. Exemplary mammalian host cells that can be used are known in the art and include immortalized cell lines obtained from the American Type Culture Collection (ATCC), including but not limited to HEK293, HEK293F, CHO, HeLa, HUVEC, HUAEC, Huh7, HepG2, BHK, MT-2, Cos-7, Cos-1, C127, 3T3, human foreskin fibroblasts (HFF), bone marrow fibroblasts, Bowes melanoma, primary neural cells or epithelial cells. In the BacMam system, baculovirus expression vectors are used to deliver genes to mammalian cells.

[0084] Generation method

[0085] The present invention further provides a method for producing a vaccine composition comprising the multimeric complex, comprising:

[0086] (i) culturing the host cell of the present invention;

[0087] (ii) obtaining a multimeric complex;

[0088] (iii) and mixing the multimeric complex with a pharmaceutically acceptable carrier or adjuvant.

[0089] It should be noted that the embodiments described in the context of the multiplexes of the invention also apply mutatis mutandis to the methods of the invention.

[0090] The multimeric complex can be expressed in a host cell, preferably an insect cell or a mammalian cell, by using a baculovirus (e.g., a baculovirus expression system or a BacMam expression system). An "expression vector" is defined herein as a medium for transferring genetic material to a target host cell where the genetic material can be expressed. An "expression system" is a combination of an expression vector and a host cell for the vector, which provides an environment to allow exogenous genes to be expressed in the host cell. The complex of the present invention can be expressed transiently or stably. Thus, the host cell of the present invention can be transiently transfected with the expression vector, or stably transfected with the expression vector, such as by integrating the vector into the host cell genome to produce a stable cell line.

[0091] Baculovirus expression systems are generally based on the introduction of foreign genes into non-essential viral genomic regions, such as via homologous recombination with a transfer vector containing the target gene. The resulting recombinant baculovirus may lack one of the non-essential genes (e.g., polh, v-cath, chiA), which is replaced by a foreign gene encoding a heterologous protein that can be expressed in a suitable host cell. These techniques are generally known to those skilled in the art and have been reviewed, for example, by Kosta et al. Nat Biotechnol. 2005; 23(5): 567-75. Specific methods for preparing recombinant baculovirus vectors are Baculovirus system (Invitrogen).

[0092] The recombinant baculovirus expression vector may be capable of replicating in a host cell and optionally in a prokaryotic cell such as E. coli. According to the present invention, any baculovirus expression vector derived from a baculovirus commonly used for recombinant expression of proteins may be used. For example, the baculovirus vector may be derived from, for example, AcMNPV, Bombyx mori (Bm) NPV, Helicoverpa armigera (Hear) NPV, or Spodoptera exigua (Se) MNPV. The baculovirus vector may be a bacmid.

[0093] It should be noted that, as used herein, the singular forms "a", "an", and "the" include the plural reference unless the context clearly indicates otherwise. Thus, for example, reference to "an expression cassette" includes one or more of the expression cassettes disclosed herein, and reference to "the method" includes reference to equivalent steps and methods known to those of ordinary skill in the art that can modify or replace the methods described herein.

[0094] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" will be understood to mean including the stated integer steps, or set of integers or steps, without excluding any other integers or steps, or sets of integers or steps. When used herein, the term "comprising" can be replaced with the term "containing" or with the term "having" when used herein.

[0095] When used herein, "consisting of" excludes any element, step or component not specified in the claim elements. When used herein, "consisting essentially of" does not exclude materials or steps that do not substantially affect the basic and novel features of the claim. In each instance herein, any one of the terms "comprises / comprising", "consisting essentially of" and "consisting of" may be replaced by any one of the other two terms.

[0096] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. It also includes specific numbers, such as, about 20 includes 20.

[0097] Unless otherwise defined herein, the scientific and technological terms used in conjunction with the present invention should have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context otherwise provides, the terms in the singular should include the plural form and the terms in the plural form should include the singular form. The methods and techniques of the present invention are usually implemented according to conventional methods well known in the art. In general, the nomenclature used in conjunction with the techniques of biochemistry, enzymology, molecule and cell biology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein is well known in the art and is commonly used.

[0098] Unless otherwise indicated, the methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); Ausubel et al., Current Protocols in Molecular Biology, J, Greene Publishing Associates (1992, and Supplements to 2002); Handbook of Biochemistry: Section A Proteins, Vol I 1976 CRC Press; Handbook of Biochemistry: Section A Proteins, Vol II 1976 CRC Press. The nomenclature used in connection with the molecular and cellular biology, protein biochemistry, enzymology, and medicinal chemistry described herein and the experimental procedures and techniques thereof are those well known and commonly used in the art. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] Figure 1 : The amino acid sequence of the HSV protein of the present invention

[0100] Figure 2 : Example of SDS-PAGE and Western blot showing UL21 / UL16 / UL11-His trimer

[0101] Figure 3 : Example of SDS-PAGE showing UL48-His / UL49-His dimer

[0102] Figure 4 : Example of size exclusion chromatography showing UL48-His / UL49-His dimer

[0103] Figure 5 : Example of SDS-PAGE and Western blot showing UL31-His / UL34 dimer

[0104] Figure 6 : Example of SDS-PAGE and Western blot showing UL31 / UL34-His dimer

[0105] Figure 7: Example of SDS-PAGE and Western blot showing UL31 / UL34-His dimer

[0106] Figure 8 : UL31 / UL34 dimer ELISPOT of infected guinea pigs

[0107] Fig. 9 : UL31 / UL34 dimer ELISPOT of patient PBMC

[0108] Fig.10 : UL48 / UL49 dimer ELISPOT of patient PBMC

[0109] Fig.11 : UL48 / UL49 dimer ELISPOT of patient PBMC

[0110] Fig.12 : UL11 / UL16 / UL21 trimer ELISPOT of patient PBMC

[0111] Fig.13 : UL11 / UL16 / UL21 trimer ELISPOT of patient PBMC

[0112] Fig.14 :Luminex analysis of UL31 / UL34 dimers in patient PBMCs

[0113] Fig.15 :Luminex analysis of UL48 / UL49 dimers in patient PBMCs

[0114] Fig.16 :Luminex analysis of UL11 / UL16 / UL21 trimers in patient PBMCs DETAILED DESCRIPTION

[0115] The following examples illustrate the present invention but should not be construed as limiting the scope of the invention.

[0116] Embodiment 1:

[0117] UL21 / UL16 / UL11-His trimer is expressed in Hi-5 insect cells and released from cell mass after suitable lysis. IMAC and 0-500mM imidazole buffer system (50mM Hepes, 500mM NaCl, pH 7.0, 1mM TCEP, 10% glycerol) are subsequently adopted to purify this trimer. Impurities are washed out by applying 25mM imidazoles in post. Then, this trimer adopts 250mM imidazole elution, and is dialyzed in Hepes buffer (50mM Hepes, 150mM NaCl, pH 7.0, 0.5mM TCEP, 10% glycerol) without imidazoles subsequently. Figure 2 (A) shows an example of SDS-PAGE. The faint band on this blot represents UL11-His, however, this faint band was visualized using an anti-His antibody. Figure 2 (B) shows an example of a Western blot using an anti-His antibody to detect UL11-His. Labeling in two examples: 1, Standard, 2, Filtered supernatant, 3, Cell pellet, 4, Flowthrough, 5-10, Fractions A5, B9, B11, C3, C6, E6, 11, Pool of fractions B9-C3, 12, Dialyzed pellet, 13, Dialyzed supernatant, 14, Filtered protein.

[0118] Embodiment 2:

[0119] UL48-His / UL49-His dimer is expressed in Hi-5 insect cells and released from cell mass after appropriate lysis. IMAC and 0-500mM imidazole buffer system (TBS buffer, 500mM NaCl, pH 7.4) are subsequently adopted to purify this dimer. Impurities are washed off by applying 50mM imidazoles in post. Then, this dimer adopts 350mM imidazole elution, and is dialyzed in TBS buffer (TBS buffer, 500mM NaCl, pH 7.4, 10% glycerol) that does not contain imidazoles subsequently. Product is further subjected to size exclusion chromatography (SEC) to prove the existence of this dimer. There is the peak corresponding to the expected size (size) of UL48-His / UL49-His dimer. Figure 3 (A) shows an example of SDS-PAGE before SEC. Labeling: 1, standard-a, 2, supernatant, 3, debris pellet, 4, filtered supernatant, 5, wash of unbound fraction, 6-14, fractions 2A9, 2A12, 2C4, 2C10, 2C12, filtered 2C12, 2D2, 2D6, 2D7. Figure 3(B) and (C) show examples of SDS-PAGE of samples after SEC and acetone precipitation. The gel shown in panel (C) is the same as in (B), but it is overexposed to better visualize low intensity bands. Labels: 1, Standard-b, 2-9, SEC acetone precipitated fractions A8, A12, B1, B2, B3, B4, B5, B6, 10, Standard-a, 11, Pooled IMAC of fractions 2C11, 2D1 and 2D2 (Pool IMAC), 12, Pooled IMAC dialysate, 13, Pooled IMAC dialysate supernatant, 14, Pooled IMAC pellets, 15, Pooled IMAC filtered proteins.

[0120] Embodiment 3:

[0121] Size exclusion chromatography (SEC) was performed to analyze the UL48-His / UL49-His products in TBS buffer, 500 mM NaCl, pH 7.4. The run was performed using a Superdex 200 Increase 10 / 300 GL SEC column and a flow rate of 0.5 mL / min. 3 mg / mL BSA was used as a standard to calibrate the column. Figure 4 In (A), the peaks at retention volumes of 12.36 and 14.21 mL correspond to the dimer and monomer (66 kDa) of the BSA calibration standard, respectively. Figure 4 In (B), the major peak at 12.93 mL represents the UL48 / UL49 dimer, while the peak at 12.16 mL probably corresponds to the tetramer formation of UL48 and UL49 subunits. Figure 4 (C) shows an overlay of the two independent runs shown in (A) and (B). The inlet shows a magnified view of the region between 8.5 and 18 mL retention volume.

[0122] Embodiment 4:

[0123] The UL31-His / UL34 dimer was expressed in Hi-5 insect cells and released from the cell pellet after appropriate lysis. The dimer was subsequently purified using IMAC and a 0-500 mM imidazole continuous gradient buffer system (50 mM Hepes, 500 mM NaCl, pH 7.0, 1 mM TCEP). Figure 5 (A) shows an example of SDS-PAGE. One of the two most concentrated fractions is marked with an asterisk. Figure 5(B) shows an example of a Western blot using an anti-His antibody to detect UL31-His. Labeling in two examples: 1, Standard, 2, Supernatant, 3, Filtered Supernatant, 4, Cell Pellets, 5, Flowthrough, 6, Wash of Unbound Protein, 7-13, Fractions A8, A10, B4, B8, B11, C2, C7.

[0124] Embodiment 5:

[0125] UL31 / UL34-His dimer was expressed in Hi-5 insect cells and released from the cell pellet after appropriate lysis. The dimer was subsequently purified using IMAC and a 25-500 mM imidazole continuous gradient buffer system (50 mM Hepes, 500 mM NaCl, pH 7.0, 1 mM TCEP). Figure 6 (A) shows an example of SDS-PAGE. One of the two most concentrated fractions is marked with an asterisk. Figure 6 (B) shows an example of a Western blot using an anti-His antibody to detect UL34-His. Labeling in both examples: 1, Standard, 2, Supernatant, 3, Filtered Supernatant, 4, Cell Pellets, 5, Flowthrough, 6, Wash of Unbound Protein, 7-13, Fractions A8, A10, B4, B8, B11, C2, C7.

[0126] Embodiment 6:

[0127] UL31 / UL34-His dimer is expressed in Hi-5 insect cells and released from cell mass after appropriate lysis. IMAC and 0-500mM imidazole buffer system (50mM Hepes, 500mM NaCl, pH 7.0, 1mM TCEP, 10% glycerol) are subsequently used to purify the dimer. Impurities are washed out in two steps by applying 50mM and 75mM imidazoles in the post. Then, the dimer is eluted with 350mM imidazoles and then dialyzed in the Hepes buffer (50mM Hepes, 500mM NaCl, pH 7.0, 0.5mM TCEP, 10% glycerol) without imidazoles. Figure 7 (A) shows an example of SDS-PAGE. Figure 7(B) shows an example of a Western blot performed using an anti-His antibody to detect UL34-His. Labeling in two examples: 1, standard, 2, culture cell pellet, 3, lysate, 4, supernatant, 5, crude pellet, 6, filtered supernatant, 7, flowthrough, 8-16, fractions B12, C2, C5, C7, C11 and F1, 17, pool of fractions C3-C7, 18, total dialyzed material, 19, dialyzed supernatant, 20, dialyzed pellet, 21, filtered protein.

[0128] Embodiment 7:

[0129] Splenocytes (1×10 5 Cells were mixed with 20 μg / mL of HSV-2 UL31 / UL34 complex. The cells were then transferred to ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates (Multiscreen HTS Plates; Millipore) and incubated for 20 hours. The plates were then developed according to the standard ELISPOT protocol, and IFN-γ-secreting cells were quantified as points using an automatic reader. Unstimulated cells and 20 μg / mL of PHA were used as negative and positive controls, respectively. The results are shown in Figure 8 .

[0130] Embodiment 8:

[0131] PBMCs from 14 HSV-2 infected individuals and 6 uninfected individuals were thawed and allowed to rest overnight. 5 Cells were plated on ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates at 10 cells / well. The cells were then stimulated with 5 μg / mL of HSV-2 UL31 / UL34 complex for 48 h. The plates were then developed according to the standard ELISPOT protocol, and IFN-γ-secreting cells were counted as points using an automatic reader. The background signal (generated by cells stimulated with buffer) was subtracted from each well, and the results were expressed as 2 × 10 5 The results are shown in Fig. 9 The HSV-2 proteins UL31 and UL34 are not expressed as monomers, but only as dimers (personal observation, data not shown). Therefore, they cannot be expressed as shown for the UL48 / UL49 and UL11 / UL16 / UL21 complexes (see Fig.10 and 12 ), comparing the responses of the UL31 / UL34 complex with those of the individual monomers.

[0132] Embodiment 9:

[0133] PBMCs from four HSV-2 infected individuals and two uninfected individuals were thawed and allowed to rest overnight. 5 Cells were plated onto ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates at 10 cells / well. The cells were then stimulated for 48 hours with 5 μg / mL of HSV-2 UL48 / UL49 complex or the corresponding monomers normalized to the amount of individual proteins in the complex. The plates were then developed according to the manufacturer's instructions, and IFN-γ-secreting cells were counted as points using an automatic reader. The background signal (generated by cells stimulated with buffer) was subtracted from each well, and the results were expressed as 2 × 10 5 The results are shown in Fig.10 The responses of uninfected individuals are shown here as average values.

[0134] Embodiment 10:

[0135] PBMCs from 14 HSV-2 infected individuals and 6 uninfected individuals were thawed and allowed to rest overnight. 5 Cells were plated on ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates at 10 cells / well. The cells were then stimulated with 5 μg / mL of HSV-2 UL48 / UL49 complex for 48 h. The plates were then developed according to the manufacturer's instructions, and IFN-γ-secreting cells were counted as points using an automatic reader. The background signal (generated by cells stimulated with buffer) was subtracted from each well, and the results were expressed as 2 × 10 5 The results are shown in Fig.11 .

[0136] Embodiment 11:

[0137] PBMCs from four HSV-2 infected individuals and two uninfected individuals were thawed and allowed to rest overnight. 5 Cells were plated onto ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates at 10 cells / well. The cells were then stimulated for 48 hours with 5 μg / mL of HSV-2 UL11 / UL16 / UL21 complex or the corresponding monomers normalized to the amount of individual proteins in the complex. The plates were then developed according to the manufacturer's instructions, and IFN-γ-secreting cells were counted as points using an automatic reader. The background signal (generated by cells stimulated with buffer) was subtracted from each well, and the results were expressed as 2 × 10 5 The results are shown in Fig.12 The responses of uninfected individuals are shown here as average values.

[0138] Embodiment 12:

[0139] PBMCs from 14 HSV-2 infected individuals and 6 uninfected individuals were thawed and allowed to rest overnight. 5 Cells were plated on ELISPOT anti-interferon gamma (IFN-γ) antibody-coated plates at 10 cells / well. The cells were then stimulated with 5 μg / mL of HSV-2 UL11 / UL16 / UL21 complex for 48 h. The plates were then developed according to the manufacturer's instructions, and IFN-γ-secreting cells were counted as points using an automatic reader. The background signal (generated by cells stimulated with buffer) was subtracted from each well, and the results were expressed as 2 × 10 5 The results are shown in Fig.13 .

[0140] Embodiment 13:

[0141] PBMCs from four HSV-2 infected individuals and two uninfected individuals were thawed and allowed to rest overnight. Cells were plated at 5 × 10 5 Cells / well were inoculated onto a plate and then stimulated with 5 μg / mL of HSV-2 UL31 / UL34 complex for 48 h. The supernatant was then collected and analyzed for IFN-γ secretion using a Luminex instrument. Background signal (generated by cells stimulated with buffer) was subtracted from each well and the results were expressed as pg / ml. Results are shown in Fig.14 .

[0142] Embodiment 14:

[0143] PBMCs from four HSV-2 infected individuals and two uninfected individuals were thawed and allowed to rest overnight. Cells were plated at 5 × 10 5 Cells / well were inoculated onto a plate and then stimulated with 5 μg / mL of HSV-2 UL48 / UL49 complex for 48 h. The supernatant was then collected and analyzed for IFN-γ secretion using a Luminex instrument. Background signal (generated by cells stimulated with buffer) was subtracted from each well and the results were expressed as pg / ml. Results are shown in Fig.15 .

[0144] Embodiment 15:

[0145] PBMCs from four HSV-2 infected individuals and two uninfected individuals were thawed and allowed to rest overnight. Cells were plated at 5 × 10 5Cells / well were inoculated onto a plate and then stimulated with 5 μg / mL of HSV-2 UL11 / UL16 / UL21 complex for 48 h. The supernatant was then collected and analyzed for IFN-γ secretion using a Luminex instrument. Background signal (generated by cells stimulated with buffer) was subtracted from each well and the results were expressed as pg / ml. Results are shown in Fig.16 .

Claims

1. A vaccine composition comprising the following multimeric complex: (i) herpes simplex virus (HSV) polypeptides UL11, UL16 and UL21, (ii) HSV polypeptides UL48 and UL49; or (iii) HSV polypeptides UL31 and UL34.

2. The vaccine composition according to claim 1, wherein the HSV polypeptide UL11 comprises an amino acid sequence having 75% or higher identity with the amino acid sequence of SEQ ID NO: 1, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL11 is capable of inducing an immune response.

3. The vaccine composition of claim 1, wherein the HSV polypeptide UL16 comprises an amino acid sequence having 72% or higher identity with the amino acid sequence of SEQ ID NO: 2, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL16 is capable of inducing an immune response.

4. The vaccine composition of claim 1, wherein the HSV polypeptide UL21 comprises an amino acid sequence having 80% or higher identity with the amino acid sequence of SEQ ID NO: 3, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL21 is capable of inducing an immune response.

5. The vaccine composition of claim 1, wherein the HSV polypeptide UL48 comprises an amino acid sequence having 80% or higher identity with the amino acid sequence of SEQ ID NO:6, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL48 is capable of inducing an immune response.

6. The vaccine composition of claim 1, wherein the HSV polypeptide UL49 comprises an amino acid sequence having 62% or higher identity with the amino acid sequence of SEQ ID NO:7, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL49 is capable of inducing an immune response.

7. The vaccine composition of claim 1, wherein the HSV polypeptide UL31 comprises an amino acid sequence having 85% or higher identity with the amino acid sequence of SEQ ID NO: 8, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide UL31 is capable of inducing an immune response.

8. The vaccine composition of claim 1, wherein the HSV polypeptide UL34 comprises an amino acid sequence having 70% or higher identity with the amino acid sequence of SEQ ID NO:9, wherein the HSV polypeptide UL34 is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

9. The vaccine composition according to any of the preceding claims, wherein the multimeric complex comprising HSV polypeptides UL11, UL16 and UL21 or HSV polypeptides UL48 and UL49 comprises HSV polypeptide gE.

10. The vaccine composition according to claim 9, wherein the HSV polypeptide gE comprises an amino acid sequence having 70% or higher identity with the amino acid sequence of SEQ ID NO:4, wherein when administered to a subject in the form of a vaccine composition, the HSV polypeptide gE is capable of inducing an immune response.

11. The vaccine composition according to any one of claims 9 or 10, wherein the HSV polypeptide gE is the cytoplasmic domain of the HSV polypeptide gE.

12. The vaccine composition of claim 11, wherein the cytoplasmic domain of the HSV polypeptide gE comprises an amino acid sequence having 80% or higher identity with the amino acid sequence of SEQ ID NO:5, wherein the cytoplasmic domain of gE is capable of inducing an immune response when administered to a subject in the form of a vaccine composition.

13. The vaccine composition of any one of the preceding claims, wherein the polypeptide is an HSV-1 polypeptide.

14. The vaccine composition of any of the preceding claims, wherein the polypeptide is an HSV-2 polypeptide.

15. The vaccine composition according to any one of the preceding claims, which is encoded by a nucleic acid.

16. The vaccine composition according to any one of the preceding claims, further comprising a pharmaceutically acceptable carrier or adjuvant.

17. A vaccine composition according to any one of the preceding claims for use in a method of inducing an immune response against HSV in a subject.

18. The vaccine composition for use according to claim 17, which is used to treat, prevent or improve HSV infection or prevent HSV reactivation.

19. The vaccine composition for use according to claim 17 or 18, wherein the HSV is HSV-1.

20. The vaccine composition for use according to claim 17 or 18, wherein the HSV is HSV-2.

21. A vector comprising (i) a polynucleotide encoding UL11, UL16 and UL21 and optionally gE or a cytoplasmic domain of said gE; (ii) a polynucleotide encoding UL48, UL49 and optionally gE or the cytoplasmic domain of said gE; or (iii) Polynucleotides encoding UL31 and UL34. A host cell comprising the vector of claim 21 .

23. A method for producing the vaccine composition of any one of claims 1 to 20, the method comprising: (i) culturing the host cell according to claim 22; (ii) obtaining a multimeric complex; (iii) and mixing the multimeric complex with a pharmaceutically acceptable carrier or adjuvant.